Aaron Reuben1, Maxwell L Elliott1, Wickliffe C Abraham2, Jonathan Broadbent3, Renate M Houts1, David Ireland4, Annchen R Knodt1, Richie Poulton4, Sandhya Ramrakha4, Ahmad R Hariri1, Avshalom Caspi1,5,6,7,8, Terrie E Moffitt1,5,6,7,8. 1. Department of Psychology and Neuroscience, Duke University, Durham, North Carolina. 2. Brain Health Research Centre, Brain Research New Zealand, Department of Psychology, University of Otago, Dunedin, New Zealand. 3. Sir John Walsh Research Institute, Faculty of Dentistry, University of Otago, Dunedin, New Zealand. 4. Dunedin Multidisciplinary Health and Development Research Unit, Department of Psychology, University of Otago, Dunedin, New Zealand. 5. Center for Genomic and Computational Biology, Duke University, Durham, North Carolina. 6. Department of Psychiatry and Behavioral Sciences, Duke University, Durham, North Carolina. 7. Social, Genetic, and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology, and Neuroscience, King's College London, London, England. 8. PROMENTA, Department of Psychology, University of Oslo, Oslo, Norway.
Abstract
Importance: Childhood lead exposure has been linked to disrupted brain development, but long-term consequences for structural brain integrity are unknown. Objective: To test the hypothesis that childhood lead exposure is associated with magnetic resonance imaging (MRI) measurements of lower structural integrity of the brain in midlife. Design, Setting, and Participants: The Dunedin Study followed a population-representative 1972-1973 birth cohort in New Zealand (N = 564 analytic sample) to age 45 years (until April 2019). Exposures: Childhood blood lead levels measured at age 11 years. Main Outcomes and Measures: Structural brain integrity at age 45 years assessed via MRI (primary outcomes): gray matter (cortical thickness, surface area, hippocampal volume), white matter (white matter hyperintensities, fractional anisotropy [theoretical range, 0 {diffusion is perfectly isotropic} to 100 {diffusion is perfectly anisotropic}]), and the Brain Age Gap Estimation (BrainAGE), a composite index of the gap between chronological age and a machine learning algorithm-estimated brain age (0 indicates a brain age equivalent to chronological age; positive and negative values represent an older and younger brain age, respectively). Cognitive function at age 45 years was assessed objectively via the Wechsler Adult Intelligence Scale IV (IQ range, 40-160, standardized to a mean of 100 [SD, 15]) and subjectively via informant and self-reports (z-score units; scale mean, 0 [SD, 1]). Results: Of 1037 original participants, 997 were alive at age 45 years, of whom 564 (57%) had received lead testing at age 11 years (302 [54%] male) (median follow-up, 34 [interquartile range, 33.7-34.7] years). Mean blood lead level at age 11 years was 10.99 (SD, 4.63) μg/dL. After adjusting for covariates, each 5-μg/dL higher childhood blood lead level was significantly associated with 1.19-cm2 smaller cortical surface area (95% CI, -2.35 to -0.02 cm2; P = .05), 0.10-cm3 smaller hippocampal volume (95% CI, -0.17 to -0.03 cm3; P = .006), lower global fractional anisotropy (b = -0.12; 95% CI, -0.24 to -0.01; P = .04), and a BrainAGE index 0.77 years older (95% CI, 0.02-1.51 years; P = .05) at age 45 years. There were no statistically significant associations between blood lead level and log-transformed white matter hyperintensity volume (b = 0.05 log mm3; 95% CI, -0.02 to 0.13 log mm3; P = .17) or mean cortical thickness (b = -0.004 mm; 95% CI, -0.012 to 0.004 mm; P = .39). Each 5-μg/dL higher childhood blood lead level was significantly associated with a 2.07-point lower IQ score at age 45 years (95% CI, -3.39 to -0.74; P = .002) and a 0.12-point higher score on informant-rated cognitive problems (95% CI, 0.01-0.23; P = .03). There was no statistically significant association between childhood blood lead levels and self-reported cognitive problems (b = -0.02 points; 95% CI, -0.10 to 0.07; P = .68). Conclusions and Relevance: In this longitudinal cohort study with a median 34-year follow-up, higher childhood blood lead level was associated with differences in some MRI measures of brain structure that suggested lower structural brain integrity in midlife. Because of the large number of statistical comparisons, some findings may represent type I error.
Importance: Childhood lead exposure has been linked to disrupted brain development, but long-term consequences for structural brain integrity are unknown. Objective: To test the hypothesis that childhood lead exposure is associated with magnetic resonance imaging (MRI) measurements of lower structural integrity of the brain in midlife. Design, Setting, and Participants: The Dunedin Study followed a population-representative 1972-1973 birth cohort in New Zealand (N = 564 analytic sample) to age 45 years (until April 2019). Exposures: Childhood blood lead levels measured at age 11 years. Main Outcomes and Measures: Structural brain integrity at age 45 years assessed via MRI (primary outcomes): gray matter (cortical thickness, surface area, hippocampal volume), white matter (white matter hyperintensities, fractional anisotropy [theoretical range, 0 {diffusion is perfectly isotropic} to 100 {diffusion is perfectly anisotropic}]), and the Brain Age Gap Estimation (BrainAGE), a composite index of the gap between chronological age and a machine learning algorithm-estimated brain age (0 indicates a brain age equivalent to chronological age; positive and negative values represent an older and younger brain age, respectively). Cognitive function at age 45 years was assessed objectively via the Wechsler Adult Intelligence Scale IV (IQ range, 40-160, standardized to a mean of 100 [SD, 15]) and subjectively via informant and self-reports (z-score units; scale mean, 0 [SD, 1]). Results: Of 1037 original participants, 997 were alive at age 45 years, of whom 564 (57%) had received lead testing at age 11 years (302 [54%] male) (median follow-up, 34 [interquartile range, 33.7-34.7] years). Mean blood lead level at age 11 years was 10.99 (SD, 4.63) μg/dL. After adjusting for covariates, each 5-μg/dL higher childhood blood lead level was significantly associated with 1.19-cm2 smaller cortical surface area (95% CI, -2.35 to -0.02 cm2; P = .05), 0.10-cm3 smaller hippocampal volume (95% CI, -0.17 to -0.03 cm3; P = .006), lower global fractional anisotropy (b = -0.12; 95% CI, -0.24 to -0.01; P = .04), and a BrainAGE index 0.77 years older (95% CI, 0.02-1.51 years; P = .05) at age 45 years. There were no statistically significant associations between blood lead level and log-transformed white matter hyperintensity volume (b = 0.05 log mm3; 95% CI, -0.02 to 0.13 log mm3; P = .17) or mean cortical thickness (b = -0.004 mm; 95% CI, -0.012 to 0.004 mm; P = .39). Each 5-μg/dL higher childhood blood lead level was significantly associated with a 2.07-point lower IQ score at age 45 years (95% CI, -3.39 to -0.74; P = .002) and a 0.12-point higher score on informant-rated cognitive problems (95% CI, 0.01-0.23; P = .03). There was no statistically significant association between childhood blood lead levels and self-reported cognitive problems (b = -0.02 points; 95% CI, -0.10 to 0.07; P = .68). Conclusions and Relevance: In this longitudinal cohort study with a median 34-year follow-up, higher childhood blood lead level was associated with differences in some MRI measures of brain structure that suggested lower structural brain integrity in midlife. Because of the large number of statistical comparisons, some findings may represent type I error.
Authors: Mohamad Habes; Guray Erus; Jon B Toledo; Tianhao Zhang; Nick Bryan; Lenore J Launer; Yves Rosseel; Deborah Janowitz; Jimit Doshi; Sandra Van der Auwera; Bettina von Sarnowski; Katrin Hegenscheid; Norbert Hosten; Georg Homuth; Henry Völzke; Ulf Schminke; Wolfgang Hoffmann; Hans J Grabe; Christos Davatzikos Journal: Brain Date: 2016-02-24 Impact factor: 13.501
Authors: Franziskus Liem; Gaël Varoquaux; Jana Kynast; Frauke Beyer; Shahrzad Kharabian Masouleh; Julia M Huntenburg; Leonie Lampe; Mehdi Rahim; Alexandre Abraham; R Cameron Craddock; Steffi Riedel-Heller; Tobias Luck; Markus Loeffler; Matthias L Schroeter; Anja Veronica Witte; Arno Villringer; Daniel S Margulies Journal: Neuroimage Date: 2016-11-23 Impact factor: 6.556
Authors: Andrew T Marshall; Samantha Betts; Eric C Kan; Rob McConnell; Bruce P Lanphear; Elizabeth R Sowell Journal: Nat Med Date: 2020-01-13 Impact factor: 53.440
Authors: Kim M Cecil; Christopher J Brubaker; Caleb M Adler; Kim N Dietrich; Mekibib Altaye; John C Egelhoff; Stephanie Wessel; Ilayaraja Elangovan; Richard Hornung; Kelly Jarvis; Bruce P Lanphear Journal: PLoS Med Date: 2008-05-27 Impact factor: 11.069
Authors: Maxwell L Elliott; Daniel W Belsky; Annchen R Knodt; David Ireland; Tracy R Melzer; Richie Poulton; Sandhya Ramrakha; Avshalom Caspi; Terrie E Moffitt; Ahmad R Hariri Journal: Mol Psychiatry Date: 2019-12-10 Impact factor: 15.992
Authors: Jo Wrigglesworth; Ian H Harding; Phillip Ward; Robyn L Woods; Elsdon Storey; Bernadette Fitzgibbon; Gary Egan; Anne Murray; Raj C Shah; Ruth E Trevaks; Stephanie Ward; John J McNeil; Joanne Ryan Journal: J Alzheimers Dis Rep Date: 2022-04-04
Authors: Aaron Reuben; Terrie E Moffitt; Wickliffe C Abraham; Antony Ambler; Maxwell L Elliott; Ahmad R Hariri; Honalee Harrington; Sean Hogan; Renate M Houts; David Ireland; Annchen R Knodt; Joan Leung; Amber Pearson; Richie Poulton; Suzanne C Purdy; Sandhya Ramrakha; Line J H Rasmussen; Karen Sugden; Peter R Thorne; Benjamin Williams; Graham Wilson; Avshalom Caspi Journal: Brain Commun Date: 2022-10-06
Authors: Clara G Sears; Bruce P Lanphear; Yingying Xu; Aimin Chen; Kimberly Yolton; Joseph M Braun Journal: J Expo Sci Environ Epidemiol Date: 2021-11-02 Impact factor: 5.563